Beam Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 03 2023 - 6:30AM
Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company
developing precision genetic medicines through base editing, today
announced that management will present at the 41st Annual J.P.
Morgan Healthcare Conference on Monday, Jan. 9, 2023 at 11:15 a.m.
PT in San Francisco.
The live webcast will be available in the investor section of
the company's website at www.beamtx.com. The webcast will be
archived for 60 days following the presentation.
About Beam Therapeutics
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company
committed to establishing the leading, fully integrated platform
for precision genetic medicines. To achieve this vision, Beam has
assembled a platform that includes a suite of gene editing and
delivery technologies and is in the process of building internal
manufacturing capabilities. Beam’s suite of gene editing
technologies is anchored by base editing, a proprietary technology
that is designed to enable precise, predictable and efficient
single base changes, at targeted genomic sequences, without making
double-stranded breaks in the DNA. This has the potential to enable
a wide range of potential therapeutic editing strategies that Beam
is using to advance a diversified portfolio of base editing
programs. Beam is a values-driven organization committed to its
people, cutting-edge science, and a vision of providing life-long
cures to patients suffering from serious diseases.
Contacts:
Investors:Chelcie ListerTHRUST Strategic
Communicationschelcie@thrustsc.com
Media:Dan Budwick1ABdan@1abmedia.com
Beam Therapeutics (NASDAQ:BEAM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Beam Therapeutics (NASDAQ:BEAM)
Historical Stock Chart
From Apr 2023 to Apr 2024